The nano-carriers were delivered intravenously to the model mice 3 times (n = 6 per group) at 5, 10 and 15 days after HER2+ 4T1-Luc cells inoculation, the bioluminescence of HER2+ 4T1-Luc tumor was monitored to track the growth and development of metastatic tumors invivo (Fig. 8A). The gene discussed is ERBB2; the disease is metastatic neoplasm.